On this page
This entry or formulation may be investigational and may not correspond to an FDA-approved product; safety and efficacy may not have been established. Kairo lists it for identification and record-keeping only.
Overview
Product & regulatory status
The cited obesity trial evaluated an investigational oral product.
Central neurotransmitters
The study describes inhibition of presynaptic uptake of three monoamines, a rationale for effects on appetite rather than peptide-hormone replacement. [1]
What the evidence shows
Published concern about this trial
The Lancet issued an Expression of Concern about this 2008 obesity trial in 2013. Its reported efficacy and tolerability should therefore be interpreted cautiously; the notice is not itself a retraction. [2]
Phase 2 obesity results
A 24-week trial randomized 203 adults with obesity to tesofensine or placebo alongside an energy-restricted diet. Active-treatment groups lost more weight, but only 79% completed the study. [1]
Limits of the comparison
The study compared with placebo, not current incretin therapies. Its authors called for confirmatory phase 3 evidence; historical claims of superiority should not be carried forward to today’s medicines. [1]
What remains unknown
This trial cannot establish long-term cardiovascular safety or the safety of combinations with other medicines affecting monoamines.
Safety
Heart rate and tolerability
Reported effects included dry mouth, bowel symptoms, nausea, and insomnia. Heart rate increased in one studied group, making cardiovascular context relevant. [1]
Oral study product
The trial used an oral formulation. Its results do not verify the identity or concentration of products bought from an unrelated supplier. [1]
Understanding product quality
Compounded drugs are not FDA-approved finished products. Poor preparation can cause contamination or incorrect strength. A catalog entry or a research paper is not a quality assessment of your product. [3]
When to seek urgent help
Severe allergic symptoms such as trouble breathing, throat or tongue swelling, or fainting need immediate help. Call 911 or your local emergency number. This is general emergency information, not a complete list of risks for this compound. [4]
A starting point for discussion
This is not a complete list of adverse effects or interactions. Your health history, other medicines, and the exact formulation matter. Missing safety data is not evidence of safety.
Common questions
Is tesofensine a peptide or a GLP-1 agonist?
Neither. Its monoamine-reuptake mechanism is a different drug class.
Questions for your clinician
Does the evidence match my condition and this exact product? What risks or interactions matter for me? How would we assess whether it is helping?
Sources
- Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial2008 · Primary research · PubMed
- Expression of concern—effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients2013 · Lancet editorial notice · PMID 23561987
- Compounding and the FDA: Questions and AnswersFDA · product quality and regulation
- AnaphylaxisMedlinePlus · recognizing an emergency
Educational information, not a recommendation to use a compound. Kairo does not give dosing advice. Review decisions with a licensed healthcare professional.